Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
indium In 111 DOTA anti-CEA monoclonal antibody M5A
- Development stage
- Unknown
- Lead developer
- City of Hope Comprehensive Cancer Center
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Indium In 111 DOTA anti-CEA monoclonal antibody M5A** is an investigational SPECT radioimmunoconjugate comprising the humanized anti-carcinoembryonic antigen monoclonal antibody hT84.66-M5A conjugated to DOTA and labeled with indium-111. It selectively binds carcinoembryonic antigen on CEA-expressing tumor cells, enabling scintigraphic localization of tumor deposits and estimation of biodistribution before administration of therapeutic radiolabeled M5A products such as yttrium-90-DOTA-M5A. It was evaluated in a phase 1 City of Hope study in patients with advanced CEA-producing malignancies, where imaging identified tumor targeting and, in some patients, previously unrecognized brain metastases.
- Other names
- 111In-DOTA-anti-CEA M5A111In-DOTA-anti-CEA monoclonal antibody M5A111In-DOTA-M5Aindium In 111 anti-CEA monoclonal antibody M5A
02
Targets
CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)
Beyond the preview
Go deeper on indium In 111 DOTA anti-CEA monoclonal antibody M5A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on indium In 111 DOTA anti-CEA monoclonal antibody M5A.